GRAFTYS initiates clinical trial
GRAFTYS has initiated a clinical study designed to demonstrate the effectiveness of a local treatment to prevent osteoporotic fractures. Evaluation of this prospective, comparative, blinded study will involve safety and efficacy of a minimally invasive femoroplasty using an injectable and resorbable bisphosphonateloaded synthetic bone substitute to prevent contralateral hip fracture after osteoporotic fracture. The lead investigator is Professor J.N. Argenson, University Hospital Sainte Marguerite, Marseille, France.
Contact international
Eiffel Park - Bâtiment D
415, rue Claude Nicolas Ledoux
Pôle d'Activités d'Aix en Provence
13 854 AIX EN PROVENCE Cedex 3
Office : +33(4) 42 60 30 00
Fax : +33(4) 42 60 30 11
France
Contact
Contact USA
NaviMed International LLC
US representation for Graftys SA
office: 847-573-1028
fax: 847-557-9089
Chicago, IL, USA
Contact
